Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;5(6):338-53.
doi: 10.1177/1756287213505672.

Recent developments in the treatment of renal cell carcinoma

Janice P Dutcher  1
Affiliations
Review

Recent developments in the treatment of renal cell carcinoma

Janice P Dutcher. Ther Adv Urol. 2013 Dec.

Abstract

Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.

Keywords: Renal cell carcinoma; immunotherapy; molecular subtypes; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Dutcher is a consultant and speaker for Prometheus, Pfizer, Novartis, and a member of data safety committees for BMS, Merck.

References

    1. Adjei A., Schwartz B., Garmey E. (2011) Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. The Oncologist 16: 788–799 - PMC - PubMed
    1. Adley B., Smith N., Nayar R., Yang X. (2006) Birt–Hogg–Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 130: 1865–1870 - PubMed
    1. Amin A., Dudek A., Logan T., Lance R., Holzbeierlien J., Master V., et al. (2013) Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC. J Clin Oncol 31(Suppl. 6): abstract 357.
    1. Argani P., Lal P., Hutchinson B., Lui M., Reuter V., Ladanyi M. (2003) Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27: 750–761 - PubMed
    1. Astuti D., Latif F., Dallol A., Dahlia P., Douglas F., George E., et al. (2001) Gene mutation in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69: 49–54 - PMC - PubMed